ArticleResearch in pharmaceutical sciences2025
Expression of PPAR-alpha and gamma in breast cancer patients and their relationship with the expression of FASN, ACSL4, and ACLY genes.
Article in Research in pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Peroxisome proliferator-activated receptors alpha and gamma (PPAR-α and PPAR-γ) are nuclear receptor proteins that play a crucial role in the regulation of cellular differentiation, development, metabolism, and tumorigenesis. Their expression levels have been implicated in the metabolic reprogramming of breast cancer cells, influencing their proliferation and survival. This study investigates the expression of PPAR-α and PPAR-γ in breast cancer and explores their relationship with key enzymes involved in fatty acid biosynthesis: fatty acid synthase (FASN), acyl-CoA synthetase long-chain family member (ACSL4), and ATP citrate lyase (ACLY). Experimental approach: In this study, 28 pairs of fresh samples of breast cancer and adjacent non-cancerous tissue were analyzed to assess gene expression levels using quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry staining. Findings/Results: The expression of PPAR-α increased, while PPAR-γ decreased significantly in breast cancer tissues compared to adjacent normal tissues. The expression of PPAR-α was significantly associated with FASN mRNA expression. Additionally, a correlation was also observed between the expression levels of both PPAR-α and PPAR-γ with ACSL4 mRNA levels. Conclusion and implications: Given the obtained results, the involvement of PPARs in the regulation of lipid metabolism was substantiated. Moreover, the correlation of PPARs with ACSL4 highlights the possible role of PPAR-α and PPAR-γ in the regulation of tumor tissue ferroptosis and suggests that targeting these pathways could offer new therapeutic strategies for managing breast cancer. However, further studies are needed to understand the mechanism of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.